228
- de La Forest DM, Gottenberg JE, Salliot C. Safety of biologic DMARDs in RA patients in real
life: a systematic literature review and meta-analyses of biologic registers. Joint Bone Spine.
2016;84(2):133–40. - Olsen CM, Hyrich KL, Knight LL, et al. Melanoma risk in patients with rheumatoid arthritis
treated with tumour necrosis factor alpha inhibitors: a systematic review and meta-analysis.
Melanoma Res. 2016;26:517–23. - Herrinton LJ, Liu L, Weng X, et al. Role of thiopurine and anti-TNF therapy in lymphoma in
inflammatory bowel disease. Am J Gastroenterol. 2011;106:2146–53. - Weidmann E. Hepatosplenic T cell lymphoma. A review on 45 cases since the first report
describing the disease as a distinct lymphoma entity in 1990. Leukemia. 2000;14:991–7. - Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with inf-
liximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol
Nutr. 2007;44:265–7. - Mackey AC, Green L, Leptak C, et al. Hepatosplenic T cell lymphoma associated with inf-
liximab use in young patients treated for inflammatory bowel disease: update. J Pediatr
Gastroenterol Nutr. 2009;48:386–8. - Deepak P, Sifuentes H, Sherid M, et al. T-cell non-Hodgkin’s lymphomas reported to the FDA
AERS with tumor necrosis factor-alpha (TNF-alpha) inhibitors: results of the REFURBISH
study. Am J Gastroenterol. 2013;108:99–105. - Nyboe Andersen N, Pasternak B, Basit S, et al. Association between tumor necrosis factor-
alpha antagonists and risk of cancer in patients with inflammatory bowel disease. JAMA.
2014;311:2406–13. - Mercer LK, Lunt M, Low AL, et al. Risk of solid cancer in patients exposed to anti-tumour
necrosis factor therapy: results from the British Society for Rheumatology biologics register
for rheumatoid arthritis. Ann Rheum Dis. 2015;74:1087–93. - Lebrec H, Ponce R, Preston BD, et al. Tumor necrosis factor, tumor necrosis factor inhibition,
and cancer risk. Curr Med Res Opin. 2015;31:557–74. - Solomon DH, Kremer JM, Fisher M, et al. Comparative cancer risk associated with methotrex-
ate, other non-biologic and biologic disease-modifying anti-rheumatic drugs. Semin Arthritis
Rheum. 2014;43:489–97. - Viens LJ, Henley SJ, Watson M, et al. Human papillomavirus-associated cancers – United
States, 2008–2012. MMWR Morb Mortal Wkly Rep. 2016;65:661–6. - Rungoe C, Simonsen J, Riis L, et al. Inflammatory bowel disease and cervical neoplasia: a
population-based nationwide cohort study. Clin Gastroenterol Hepatol. 2015;13:693–700.e1. - Kane S, Khatibi B, Reddy D. Higher incidence of abnormal pap smears in women with inflam-
matory bowel disease. Am J Gastroenterol. 2008;103:631–6. - Singh H, Demers AA, Nugent Z, et al. Risk of cervical abnormalities in women with inflam-
matory bowel disease: a population-based nested case-control study. Gastroenterology.
2009;136:451–8. - Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology.
2011;140:1807–16. - Triantafillidis JK, Nasioulas G, Kosmidis PA. Colorectal cancer and inflammatory bowel
disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies.
Anticancer Res. 2009;29:2727–37. - Mellemkjaer L, Johansen C, Gridley G, et al. Crohn's disease and cancer risk (Denmark).
Cancer Causes Control. 2000;11:145–50. - Sachar DB. Cancer in Crohn's disease: dispelling the myths. Gut. 1994;35:1507–8.
- Rubin DT, Huo D, Kinnucan JA, et al. Inflammation is an independent risk factor for colonic
neoplasia in patients with ulcerative colitis: a case-control study. Clin Gastroenterol Hepatol.
2013;11:1601–8.e1-4. - Carrat F, Seksik P, Colombel JF, et al. The effects of aminosalicylates or thiopurines on
the risk of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther.
2016;45(4):533–41.
J.T. Hughes and M.D. Long